TGFB1 and type 2 diabetes mellitus: Despite the above limitations, our study is the first to show that triple combination therapy of ALA, gliclazide and ramipril prevents early development and progression of DCM in T2DM through inhibition of ROS-dependent TGF-β1/Smad pathway.